Bristol-Myers Squibb Company (BMY) has experienced a series of setbacks in its attempt to create a new generation blood thinner in partnership with Johnson & Johnson, leading to a fall in stock value. The companies decided to halt the drug trial after an unsuccessful interim review. The failure is viewed as a significant setback for Bristol-Myers. Despite this drawback, Bristol-Myers Squibb continues to make strides in the biotech industry. They expanded their strategic collaboration with the Sarah Cannon Research Institute to accelerate patient enrollment and broaden access to innovative cancer research. The company's pivotal trials and acquisition news have signalled opportunities for a turnaround following a recent 13% bounce in stock. Interestingly, they recently acquired cell therapy biotech, Orbital for $1.5 billion. Other updates indicate that stock positions in the company have fluctuated among major holders. Finally, Bristol-Myers' Q3 earnings have been described as 'bullish', indicating potential positive momentum.
Bristol-Myers Squibb News Analytics from Wed, 14 May 2025 07:00:00 GMT to Sat, 15 Nov 2025 17:29:30 GMT -
Rating -1
- Innovation 8
- Information 8
- Rumor 2
